Fractyl Health (GUTS) Expected to Announce Earnings on Monday

Fractyl Health (NASDAQ:GUTS) is projected to post its Q4 2025 resultson Monday, April 6th. Analysts expect Fractyl Health to post earnings of ($0.18) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 24, 2026 at 4:30 PM ET.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Tuesday, March 24th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.34. On average, analysts expect Fractyl Health to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Fractyl Health Stock Performance

NASDAQ GUTS opened at $0.45 on Monday. The firm’s 50-day moving average is $0.71 and its two-hundred day moving average is $1.28. Fractyl Health has a 12 month low of $0.38 and a 12 month high of $3.03. The company has a debt-to-equity ratio of 3.23, a current ratio of 4.78 and a quick ratio of 4.78. The stock has a market capitalization of $71.17 million, a P/E ratio of -0.24 and a beta of 1.51.

Institutional Trading of Fractyl Health

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE boosted its stake in shares of Fractyl Health by 23.5% in the third quarter. Bank of America Corp DE now owns 88,634 shares of the company’s stock valued at $141,000 after purchasing an additional 16,856 shares during the period. Balyasny Asset Management L.P. purchased a new stake in Fractyl Health during the 4th quarter worth approximately $132,000. Qube Research & Technologies Ltd acquired a new stake in Fractyl Health during the 2nd quarter worth approximately $129,000. Verition Fund Management LLC acquired a new stake in Fractyl Health during the 4th quarter worth approximately $121,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in Fractyl Health in the 4th quarter valued at approximately $110,000.

Key Headlines Impacting Fractyl Health

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (notably FY2026–FY2030) and trimmed near‑term loss estimates while keeping a “Buy” rating and an $8.00 price target — this signals the analyst expects meaningful recovery and eventual profitability, supporting upside versus the current sub‑$1 trade. HC Wainwright analyst note (MarketBeat)
• Positive Sentiment: Canaccord Genuity reaffirmed a “Buy” rating and an $8.00 price target, echoing the bullish analyst narrative and providing additional third‑party validation of the longer‑term thesis. Canaccord reaffirmation (Benzinga)
• Neutral Sentiment: Q4 2025 earnings call transcript is available — the company recently reported an EPS beat for Q4 (reported EPS vs. consensus), which is supportive but investors will focus on follow‑up cadence, cash runway, and clinical/regulatory catalysts. Q4 2025 earnings call transcript (MSN)
• Negative Sentiment: TipRanks flagged “significant compliance risks” under global anti‑corruption and sanctions laws after a new risk disclosure — legal/compliance issues can slow partnerships, delay commercial progress, or increase remediation costs, creating downside risk and adding near‑term uncertainty. Compliance risk disclosure (TipRanks)

Analyst Upgrades and Downgrades

GUTS has been the subject of a number of recent analyst reports. Canaccord Genuity Group reiterated a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a research report on Thursday. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th. Finally, Morgan Stanley lowered Fractyl Health from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $8.00 to $2.00 in a research report on Thursday, January 29th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Fractyl Health presently has a consensus rating of “Hold” and an average target price of $5.40.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.